Targeted drug trial aims to block Cancer's growth signal
NCT ID NCT06351371
Summary
This study is testing whether the drug erdafitinib can help control advanced solid tumors that have specific genetic changes called FGFR mutations or fusions. The drug works by blocking a faulty protein that tells cancer cells to grow. The trial enrolled 35 adults whose cancer has continued to grow despite standard treatments, to see if this targeted approach can shrink tumors or stop their progression.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT SOLID NEOPLASM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ECOG-ACRIN Cancer Research Group
Philadelphia, Pennsylvania, 19103, United States
Conditions
Explore the condition pages connected to this study.